These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Transcriptional profiling of C2C12 myotubes in response to SHIP2 depletion and insulin stimulation. Huard C; Martinez RV; Ross C; Johnson JW; Zhong W; Hill AA; Kim R; Paulsen JE; Shih HH Genomics; 2007 Feb; 89(2):270-9. PubMed ID: 17123777 [TBL] [Abstract][Full Text] [Related]
26. Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes. Ikubo M; Wada T; Fukui K; Ishiki M; Ishihara H; Asano T; Tsuneki H; Sasaoka T Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E157-64. PubMed ID: 19001549 [TBL] [Abstract][Full Text] [Related]
27. Impact of activating transcription factor 4 signaling on lipogenesis in HepG2 cells. Ren LP; Yu X; Song GY; Zhang P; Sun LN; Chen SC; Hu ZJ; Zhang XM Mol Med Rep; 2016 Aug; 14(2):1649-58. PubMed ID: 27357269 [TBL] [Abstract][Full Text] [Related]
28. Specific tyrosine phosphorylations mediate signal-dependent stimulation of SHIP2 inositol phosphatase activity, while the SH2 domain confers an inhibitory effect to maintain the basal activity. Prasad NK; Werner ME; Decker SJ Biochemistry; 2009 Jul; 48(27):6285-7. PubMed ID: 19518129 [TBL] [Abstract][Full Text] [Related]
29. IRTKS Promotes Insulin Signaling Transduction through Inhibiting SHIP2 Phosphatase Activity. Wu C; Cui X; Huang L; Shang X; Wu B; Wang N; He K; Han Z Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212584 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster model of insulin resistance: evidence for the role of sphingosine and sphinganine in hepatic VLDL-apoB100 overproduction. Dekker MJ; Baker C; Naples M; Samsoondar J; Zhang R; Qiu W; Sacco J; Adeli K Atherosclerosis; 2013 May; 228(1):98-109. PubMed ID: 23466071 [TBL] [Abstract][Full Text] [Related]
31. The lipid phosphatase SHIP2 controls insulin sensitivity. Clément S; Krause U; Desmedt F; Tanti JF; Behrends J; Pesesse X; Sasaki T; Penninger J; Doherty M; Malaisse W; Dumont JE; Le Marchand-Brustel Y; Erneux C; Hue L; Schurmans S Nature; 2001 Jan; 409(6816):92-7. PubMed ID: 11343120 [TBL] [Abstract][Full Text] [Related]
32. Antisense oligonucleotides against the lipid phosphatase SHIP2 improve muscle insulin sensitivity in a dietary rat model of the metabolic syndrome. Buettner R; Ottinger I; Gerhardt-Salbert C; Wrede CE; Schölmerich J; Bollheimer LC Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1871-8. PubMed ID: 17327370 [TBL] [Abstract][Full Text] [Related]
33. Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies. Qiu W; Avramoglu RK; Dubé N; Chong TM; Naples M; Au C; Sidiropoulos KG; Lewis GF; Cohn JS; Tremblay ML; Adeli K Diabetes; 2004 Dec; 53(12):3057-66. PubMed ID: 15561934 [TBL] [Abstract][Full Text] [Related]
34. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Suwa A; Yamamoto T; Sawada A; Minoura K; Hosogai N; Tahara A; Kurama T; Shimokawa T; Aramori I Br J Pharmacol; 2009 Oct; 158(3):879-87. PubMed ID: 19694723 [TBL] [Abstract][Full Text] [Related]
35. Reversal of denervation-induced insulin resistance by SHIP2 protein synthesis blockade. Bertelli DF; Ueno M; Amaral ME; Toyama MH; Carneiro EM; Marangoni S; Carvalho CR; Saad MJ; Velloso LA; Boschero AC Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E679-87. PubMed ID: 12453826 [TBL] [Abstract][Full Text] [Related]
36. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Zhang Y; Lei T; Huang JF; Wang SB; Zhou LL; Yang ZQ; Chen XD Mol Cell Endocrinol; 2011 Aug; 342(1-2):41-7. PubMed ID: 21664250 [TBL] [Abstract][Full Text] [Related]
37. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Sasaoka T; Wada T; Tsuneki H Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857 [TBL] [Abstract][Full Text] [Related]